Co-Diagnostics, Inc. Common Stock (CODX)
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company specializing in the development and commercialization of innovative, cost-effective diagnostic tests. The company is known for its proprietary technology platform, Logix, which enables rapid design and production of PCR-based tests for infectious diseases, including COVID-19. Co-Diagnostics focuses on providing reliable diagnostic solutions for healthcare, agriculture, and animal health markets worldwide.
Company News
Co-Diagnostics will attend the Global Health Exhibition 2025 in Riyadh, showcasing their upcoming PCR point-of-care platform and exploring a potential joint venture in the Middle East and North Africa region.
Co-Diagnostics reported a Q2 2025 GAAP EPS loss of $0.23, slightly improving from the prior year. Revenue fell sharply to $0.2 million from $2.7 million in Q2 2024, with the company still in a pre-commercial phase focused on developing infectious disease diagnostic platforms.
Elevance Health (ELV) delivered earnings and revenue surprises of 0.95% and 0.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?